Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Climb 0.9% – Should You Buy?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares traded up 0.9% during mid-day trading on Wednesday. The stock traded as high as $1.18 and last traded at $1.15. Approximately 20,960 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 86,732 shares. The stock had previously closed at $1.14.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Acurx Pharmaceuticals Price Performance

The firm’s fifty day simple moving average is $1.35 and its 200 day simple moving average is $1.68. The company has a market capitalization of $6.39 million, a PE ratio of -0.43 and a beta of -2.05.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15). On average, equities research analysts anticipate that Acurx Pharmaceuticals, Inc. will post -2.00 EPS for the current fiscal year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on antibacterial compounds designed to address pathogens that are increasingly resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, an investigational antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile or C.